Literature DB >> 21464043

Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells?

Alla Arzumanyan1, Tiffany Friedman, Irene O L Ng, Marcia M Clayton, Zhaorui Lian, Mark A Feitelson.   

Abstract

Hepatitis B virus (HBV) is a major etiologic agent of chronic liver disease and hepatocellular carcinoma (HCC). HBV-encoded X antigen, HBx, and pathways implicated in the self-renewal of stem cells contribute to HCC, but it is not clear whether HBx expression promotes "stemness." Thus, experiments were designed to test the hypothesis that HBx triggers malignant transformation by promoting properties that are characteristic of cancer stem cells (CSC). To test this hypothesis, HepG2 cells were stably transduced with HBx and then assayed for phenotypic and molecular characteristics of "stemness." The relationship between HBx and "stemness"-associated markers was also evaluated by immunohistochemical staining of liver and tumor tissue sections from HBV-infected patients. The results showed that Oct-4, Nanog, Klf-4, β-catenin, and epithelial cell adhesion molecule (EpCAM) were activated by HBx in vitro and in vivo. EpCAM was detected in the nuclei of human HCC cells from infected patients. HBx promotes "stemness" by activating β-catenin and epigenetic upregulation of miR-181, both of which target EpCAM. HBx expression was also associated with depressed levels of E-cadherin. Moreover, HBx stimulated cell migration, growth in soft agar, and spheroid formation. This work is the first to propose that HBV promotes "stemness" in the pathogenesis of HCC. HBx-associated upregulated expression of multiple "stemness" markers supports the hypothesis that HBx contributes to hepatocarcinogenesis, at least in part, by promoting changes in gene expression that are characteristics of CSCs. ©2011 AACR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21464043      PMCID: PMC3096741          DOI: 10.1158/0008-5472.CAN-10-3951

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues.

Authors:  Konrad Hochedlinger; Yasuhiro Yamada; Caroline Beard; Rudolf Jaenisch
Journal:  Cell       Date:  2005-05-06       Impact factor: 41.582

2.  The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis.

Authors:  Z Lian; J Pan; J Liu; S Zhang; M Zhu; P Arbuthnot; M Kew; M A Feitelson
Journal:  Oncogene       Date:  1999-03-04       Impact factor: 9.867

3.  Proteasome complex as a potential cellular target of hepatitis B virus X protein.

Authors:  J Huang; J Kwong; E C Sun; T J Liang
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

Review 4.  Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis.

Authors:  K Matsubara; T Tokino
Journal:  Mol Biol Med       Date:  1990-06

5.  Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin.

Authors:  Qingqing Ding; Weiya Xia; Jaw-Ching Liu; Jer-Yen Yang; Dung-Fang Lee; Jiahong Xia; Geoffrey Bartholomeusz; Yan Li; Yong Pan; Zheng Li; Ralf C Bargou; Jun Qin; Chien-Chen Lai; Fuu-Jen Tsai; Chang-Hai Tsai; Mien-Chie Hung
Journal:  Mol Cell       Date:  2005-07-22       Impact factor: 17.970

Review 6.  Wnt signaling in liver cancer.

Authors:  Yutaka Takigawa; Anthony M C Brown
Journal:  Curr Drug Targets       Date:  2008-11       Impact factor: 3.465

7.  Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.

Authors:  Taro Yamashita; Anuradha Budhu; Marshonna Forgues; Xin Wei Wang
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

Review 8.  The role of epithelial-mesenchymal transition in cancer pathology.

Authors:  Marcello Guarino; Barbara Rubino; Gianmario Ballabio
Journal:  Pathology       Date:  2007-06       Impact factor: 5.306

9.  Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling.

Authors:  Yi Tang; Krit Kitisin; Wilma Jogunoori; Cuiling Li; Chu-Xia Deng; Susette C Mueller; Habtom W Ressom; Asif Rashid; Aiwu Ruth He; Jonathan S Mendelson; John M Jessup; Kirti Shetty; Michael Zasloff; Bibhuti Mishra; E P Reddy; Lynt Johnson; Lopa Mishra
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-08       Impact factor: 11.205

10.  Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses.

Authors:  Xiaohong Liu; Li Wang; Shuhui Zhang; Jing Lin; Shunmin Zhang; Mark A Feitelson; Hengjun Gao; Minghua Zhu
Journal:  Carcinogenesis       Date:  2008-05-13       Impact factor: 4.944

View more
  53 in total

1.  pIgR: frenemy of inflammation, EMT, and HCC progression.

Authors:  Nathalie Sphyris; Sendurai A Mani
Journal:  J Natl Cancer Inst       Date:  2011-10-24       Impact factor: 13.506

2.  β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study.

Authors:  Sumiyo Ando; Junji Shibahara; Akimasa Hayashi; Masashi Fukayama
Journal:  Virchows Arch       Date:  2015-08-27       Impact factor: 4.064

3.  Hepatitis B virus X (HBx) play an anti-apoptosis role in hepatic progenitor cells by activating Wnt/β-catenin pathway.

Authors:  Lihong Shen; Xifeng Zhang; Daixi Hu; Tao Feng; Hongli Li; Yongliang Lu; Jiayi Huang
Journal:  Mol Cell Biochem       Date:  2013-08-10       Impact factor: 3.396

4.  Multiple novel hepatocellular carcinoma signature genes are commonly controlled by the master pluripotency factor OCT4.

Authors:  Chao Ye; Xiaoqian Zhang; Xinyu Chen; Qingyi Cao; Xiaobing Zhang; Yanwen Zhou; Wenxin Li; Liangjie Hong; Haiyang Xie; Xiaoli Liu; Hongcui Cao; Ying-Jie Wang; Bo Kang
Journal:  Cell Oncol (Dordr)       Date:  2019-12-17       Impact factor: 6.730

Review 5.  Significant biomarkers for the management of hepatocellular carcinoma.

Authors:  Yasuteru Kondo; Osamu Kimura; Tooru Shimosegawa
Journal:  Clin J Gastroenterol       Date:  2015-04-09

6.  SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases.

Authors:  Ta-Chiang Liu; Neeta Vachharajani; William C Chapman; Elizabeth M Brunt
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

Review 7.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.

Authors:  Alla Arzumanyan; Helena M G P V Reis; Mark A Feitelson
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

8.  Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein.

Authors:  Alla Arzumanyan; Vaishnavi Sambandam; Marcia M Clayton; Steve S Choi; Guanhua Xie; Anna Mae Diehl; Dae-Yeul Yu; Mark A Feitelson
Journal:  Cancer Res       Date:  2012-09-17       Impact factor: 12.701

9.  Cytoplasmic EpCAM over-expression is associated with favorable clinical outcomes in pancreatic cancer patients with Hepatitis B virus negative infection.

Authors:  Yao Meng; Bao-Qing Xu; Zhi-Guang Fu; Bo Wu; Bo Xu; Zhi-Nan Chen; Ling Li
Journal:  Int J Clin Exp Med       Date:  2015-12-15

Review 10.  Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma.

Authors:  Caecilia H C Sukowati; Korri E El-Khobar; Susan I Ie; Beatrice Anfuso; David H Muljono; Claudio Tiribelli
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.